A phase 1 trial of a peripheral artery disease drug candidate from TheraVasc demonstrated safety in diabetic patients. The positive clinical trial data reported by Cleveland-based TheraVasc potentially puts the young company one step closer to a development partnership with a big drug maker or a venture round between $10 million and $20 million. The […]
TheraVasc plans to begin enrolling patients this month in a phase 2a clinical trial of its pill designed to treat peripheral artery disease. The clinical trial, which is expected to follow 50 diabetic PAD patients for 11 weeks, could lead to big things for Cleveland-based TheraVasc. CEO Tony Giordano hopes a successful trial will position […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
TheraVasc Inc., which is reformulating a drug to treat vascular diseases, has raised a $1.8 million Series A1 round of investment capital. But the company isn't stopping there -- it's looking to add about $450,000 to the round.
Device maker MAX Endoscopy Inc. and drug developer TheraVasc Inc. each have received $250,000 follow-on investments from JumpStart Ventures, the investment arm of Northeast Ohio venture developer JumpStart Inc. The new commitments follow initial investments of the same amount that JumpStart made in the two companies last winter.
Theravasc Inc., a Cleveland company that is reformulating an approved drug to treat vascular diseases, has received investment commitments of $500,000 to do its initial clinical study.
TheraVasc, based in Shreveport, Louisiana, wants to raise $2.5 million in a Series A round, said President Tony Giordano. It would close on most of the money by the fall and launch a Phase Ib clinical trial to test how its drug, TV1001i, works to restore blood vessels damaged through peripheral artery disease.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.